---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-335039"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2026-08-05T20:05:32+00:00"
generated_at: "2026-08-05T20:07:06.939643+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines Q2 net loss $644M; FDA accepts daraxonrasib NDA for pancreatic cancer

## Summary
- Net loss $644.4M vs $247.8M YoY; R&D $394.9M, G&A $110.2M; cash $3.9B.
- FDA accepted daraxonrasib NDA for previously treated metastatic pancreatic cancer; Breakthrough Therapy Designation for NSCLC.
- New combo data: zoldonrasib + SOC in 1L G12D NSCLC: 82% ORR, 100% DCR; elironrasib + SOC in 1L G12C NSCLC: 85% ORR, 97% DCR.
- Completed $2.225B gross proceeds from stock and convertible note offerings; received $250M from Royalty Pharma.
- Updated FY2026 GAAP operating expense guidance to $2.1-2.2B, including $270-290M stock-based comp.

## SEC filing metadata
- accession: 0001193125-26-335039
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2026-08-05T20:05:32+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000119312526335039/0001193125-26-335039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000119312526335039/rvmd-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-335039
- JSON: https://secwatch.observer/filing/0001193125-26-335039.json
- Plain text: https://secwatch.observer/filing/0001193125-26-335039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.